Evaluation of efficacy and safety of a abobotulinum toxin type A produced by Ronak Pharmaceutical Company in comparision to the commercial product Dysport® in treating moderate-to-severe glabellar lines; A phase III randomized, double-blind,clinical trial

Start Date31 Oct 2024

Sponsor / Collaborator-

IRCT20200731048257N3 / SuspendedPhase 1

safety and effectiveness of Biosimilar Abobotulinum toxin type A in the treatment of moderate to severe frown lines, A phase I Clinical trials study

Start Date31 Oct 2024

Sponsor / Collaborator-

NCT06625060 / RecruitingPhase 2

A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults

A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers.
Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics.
This study aims to determine:
* The safety and efficacy of injecting IPN10200 directly into the muscles of the head and neck to prevent EM and CM,
* The right amount (dose) of IPN10200 to inject at each point,
* The total amount (dose) of IPN10200 that provides the best balance between safety and efficacy preventing migraines.
Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.

Start Date10 Oct 2024

Sponsor / Collaborator

Ipsen SA

100 Clinical Results associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

100 Translational Medicine associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

100 Patents (Medical) associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

2,583

Literatures (Medical) associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

01 Jan 2025·ARCHIVES OF ORAL BIOLOGY

Impact of botulinum toxin type A on tooth movement and bone remodeling in male Wistar rats

Article

Author: Guariza-Filho, Odilon ; Johann, Aline Cristina Batista Rodrigues ; Tanaka, Orlando Motohiro ; Vosgerau, Luana ; Salvação, Sara Moreira Leal ; Camargo, Elisa Souza ; Marangon, Renata Machado ; de Viveiros, Bruno Massa ; Yépez, Joana Estephany Gordillo ; Andreis, Patricia Kern Di Scala ; Ignácio, Sergio Aparecido

OBJECTIVE:

We evaluated whether the use of botulinum neurotoxin type A (BTX-A) in masticatory muscles influences tooth movement and bone remodeling.

DESIGN:

Seventy-seven male Wistar rats were allocated to the groups: S - Saline (n=20); SM - Saline with movement (n=20); BT - Botulinum toxin (n=18); BTM - Botulinum toxin with movement (n=19). On day 1, 0.02 mL of sterile 0.9 % saline was administered to groups S and SM and BTX-A (1 U in 0.02 mL of saline) to groups BT and BTM, in the masseter and temporal muscles laterally. On day 30, a nickel titanium spring was installed to move the first maxillary molar and euthanasia was performed on days 32 and 51. Tooth displacement, maxillary and mandibular bone volumes, collagen neoformation, bone and root resorptions, and masseter morphometry were assessed. Statistical analysis was conducted (p < 0.05).

RESULTS:

A higher percentage of type I collagen was observed in the BT than in the S group on day 51 and lower mass, length, and diameter of the masseter fibers in BT and BTM (p < 0.05). Tooth displacement, bone volume, bone and root resorptions, hyaline area, and masseter height showed no difference among groups with and without BTX-A, regardless of tooth movement (p > 0.05).

CONCLUSIONS:

BTX-A did not interfere with tooth displacement, bone volume, and dental and periodontal tissues related to tooth movement in rats; it increased mature collagen in animals without tooth movement; and it caused a decrease in the mass, length, and diameter of the masseter fibers.

01 Dec 2024·JOURNAL OF ELECTROMYOGRAPHY AND KINESIOLOGY

Pelvic floor muscle electrical coupling in chronic pelvic pain: Insights into pathophysiology and botulinum toxin treatment effects

Article

Author: De-Arriba, Maria ; Jose Nohales-Alfonso, Francisco ; Tarazona-Motes, Marta ; Albaladejo-Belmonte, Monica ; Garcia-Casado, Javier ; Alberola-Rubio, Jose

This study aimed to assess the electrical coupling between both pelvic floor muscle (PFM) sides (two-sided coupling) and within individual PFM sides (one-sided coupling) in chronic pelvic pain (CPP) before and after botulinum neurotoxin type A (BoNT/A) treatment. Surface electromyographic (sEMG) signals were recorded from the left and right PFM of 24 patients (P) with CPP before and after being treated with BoNT/A (Weeks 0,8,12,24). Recordings were also made in 24 healthy women (H). PFM two-sided and one-sided coupling was evaluated during contractions by the cross-correlation (CC) and the imaginary part of coherency (iCOH) of their sEMG signals. Significant differences between their values were assessed comparing P(0) vs. P(8,12,24) and H vs. P(0,8,12,24). This study showed that PFM two-sided coupling is similar across groups before treatment, while PFM one-sided coupling on the patients' most painful side is deranged before and also after BoNT/A treatment: amplitude coupling is lower (iCOH) than healthy women's. This could be justified by altered neuromotor control strategies developed as an adaptation to muscle pain, structural and electrical changes in PFM, and alterations in their innervation pattern, which may influence the onset, perpetuation, or recurrence of CPP after treatment.

01 Dec 2024·Urogynecology (Philadelphia, Pa.)

Factors Associated With Onabotulinum Toxin-A Discontinuation in a Diverse Urban Population

Article

Author: Abraham, Nitya ; Liebeskind, Mariel ; Bergeron, Tyler ; Harandi, Arshia Aalami

Importance:

Although overactive bladder (OAB) is a common condition, affecting 16% of Americans, few patients continue on to advanced therapies. Furthermore, procedural therapies like intravesical onabotulinum toxin-A (BTX-A), which require ongoing repeat treatments, have discontinuation rates ranging from 25% to 51%.

Objectives:

This study sought to investigate factors associated with dis-continuation of BTX-A injections for idiopathic OAB among a diverse urban population.

Study Design:

This was a retrospective review of adults 18 years and older who underwent BTX-A injection for idiopathic OAB. Patient demographics, past medical history, symptoms, and postprocedural outcomes such as subjective improvement, urinary retention, and incidence of urinary tract infection were compared between groups.

Results:

Onabotulinum toxin-A injections were administered to 246 patients who met study criteria, of whom 211 (85.7%) were women. One hundred (40.7%) patients discontinued BTX-A therapy. Patients discontinuing BTX-A therapy were more likely to have developed postprocedural urinary retention (18.4% vs 9.7%, P < 0.05) and had a higher median income by zip code ($59,000 vs $50,000; P < 0.01). Patients were significantly more likely to continue BTX-A therapy if they reported preprocedural nocturia (57.2% vs 36.8%, P < 0.01) or urgency urinary incontinence (UUI) (78.1% vs 64.6%, P < 0.05).

Conclusions:

Adverse outcomes, such as postprocedural urinary retention, are associated with discontinuation of BTX-A therapy. Patients who reported nocturia and UUI before injection were more likely to continue BTX-A suggesting more severe OAB is more responsive to this therapy. Given the large proportion (>40%) of patients who discontinued BTX-A treatment, further research is needed to identify barriers to continuation of care.

News (Medical) associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

23 Oct 2024

·www.globenewswire.com

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. YTD 2024 YTD 2023 % change Q3 2024 Q3 2023 % change €m €m Actual CER1 €m €m Actual CER1 Oncology 1 829,8 1 744,1 4,9% 5,8% 604,0 574,5 5,1% 5,6% Neuroscience 536,4 489,0 9,7% 11,8% 181,9 164,8 10,4% 10,1% Rare Disease 129,7 76,0 70,7% 71,3% 50,8 33,2 53,1% 54,4% Total Sales 2 495,9 2 309,1 8,1% 9,2% 836,6 772,4 8,3% 8,6% Highlights Total-sales growth in the year to date of 9.2% at CER1, or 8.1% as reported, with notable performances from Dysport® (abobotulinumtoxinA), Cabometyx® (cabozantinib) and Bylvay® (odevixibat), with robust Somatuline® (lanreotide) sales, as well as the increasing contribution from the launches of Iqirvo® (elafibranor) in 2L PBC2 and Onivyde® (irinotecan) in 1L mPDAC3 Regulatory approvals in the E.U. of Iqirvo and Kayfanda® (odevixibat)Increased 2024 financial guidance: total-sales growth greater than 8.0% at CER1 (prior guidance: greater than 7.0% at CER1); core operating margin greater than 31.0% of total sales (prior guidance: greater than 30.0%) “Since the launch of our strategy in 2020, we have enjoyed uninterrupted growth. This quarter was no exception and was accompanied by further progress in the pipeline”, commented David Loew, Chief Executive Officer. “We have also continued to launch across several indications and lines of therapy, including the recent rollouts of Iqirvo and Onivyde, which are progressing well. Supported by the performance so far this year, we are further increasing our 2024 sales and margin guidance.” “We have built a track record of delivery, grounded in a strong foundation of external innovation, commercial excellence and our ongoing mission to offer more choices for patients.” Full-year 2024 guidance Based on the strong performance in the third quarter, Ipsen has further increased its financial guidance for 2024: Total-sales growth greater than 8.0%, at constant currency (prior guidance of greater than 7.0%). Based on the average level of exchange rates in September 2024, an adverse impact on total sales of around 1.5% from currencies is expectedCore operating margin greater than 31.0% of total sales (prior guidance of greater than 30.0%) Pipeline update In September 2024, the European Commission conditionally approved Iqirvo 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a monotherapy in patients unable to tolerate UDCA. Iqirvo was approved in the same setting by the U.S. FDA in June 2024. In September 2024, the European Commission also approved Kayfanda as a treatment for pruritus in children from as young as six months of age who have Alagille syndrome (ALGS). Odevixibat, under the brand name Bylvay, is already marketed in the E.U. for the treatment of progressive familial intrahepatic cholestasis (PFIC), and in the U.S. and E.U. for PFIC, and in the U.S. for ALGS. In the same month, final results from the CABINET Phase III trial were presented at the 2024 European Society for Medical Oncology Congress and were published in the New England Journal of Medicine, reinforcing the efficacy benefits of Cabometyx in advanced neuroendocrine tumors. It was announced at that time that Ipsen had submitted an extension of indication Marketing Authorization to the European Medicines Agency. Business development In August 2024, Ipsen entered into an agreement to sell its rare pediatric disease Priority Review Voucher. As part of the agreement, Ipsen received a cash payment of $158m in the third quarter. In October 2024, Eton Pharmaceuticals entered into an agreement with Ipsen to acquire Increlex® (mecasermin injection). The transaction is expected to close before the end of 2024. Arbitration proceedings with Galderma As of 30 September 2024, two arbitration proceedings initiated by Galderma against Ipsen at the International Chamber of Commerce (ICC) were ongoing. The first dispute, initiated by Galderma in 2021, pertains to the territorial scope of the commercial partnership related to Azzalure® (abobotulinumtoxinA) and Dysport under an agreement signed in 2007 in the E.U., in certain Eastern European countries, and in Central Asia. The Tribunal of the ICC Internal Court of Arbitration issued a final award, in October 2024, dismissing most, if not all, of Galderma's claims in this first arbitration and ordered that Galderma bear the majority of the legal fees and arbitration costs incurred by Ipsen. A second dispute was initiated by Galderma in November 2023, related to the validity of Ipsen’s 2023 termination of a joint R&D collaboration agreement entered into in 2014 under the parties’ respective early-stage neurotoxin programs, including the development of IPN10200. At this stage, Ipsen cannot reasonably predict any potential financial impact from this final remaining arbitration process, for which it intends to fully defend and vindicate its rights. Conference call A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here; webcast details can be found here. Calendar Ipsen intends to publish its full-year and fourth-quarter results on 13 February 2025. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the nine-month period to 30 September 2024 (YTD 2024) and the three-month period to 30 September 2024 (Q3 2024), compared to the nine-month period to 30 September 2023 (YTD 2023) and the three-month period to 30 September 2023 (Q3 2023), respectively. Commentary is based on the performance in YTD 2024, unless stated otherwise. About Ipsen Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fuelled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. Ipsen contacts Investors Craig Marks +44 (0)7584 349 193 Nicolas Bogler +33 6 52 19 98 92 Media Jennifer Smith-Parker +44 (0) 7843 137 764Anne Liontas +33 7 67 34 72 96 1 At constant exchange rates (CER), which excludes any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.2 Second-line primary biliary cholangitis.3 First-line metastatic pancreatic ductal adenocarcinoma. Attachment Ipsen - YTD 2024 sales announcement

Drug ApprovalPhase 3Clinical ResultLicense out/in

25 Sep 2024

·www.prnewswire.com

The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA

CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned subsidiary, Claruvis Pharmaceutical Co., has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for YY003, the world's first liquid formulation of recombinant BoNT/A, packaged in a pre-filled syringe, developed for the treatment of glabellar lines. "We are thrilled to receive FDA approval to advance the novel liquid formulation of rBoNT/A (YY003) into clinical development. This liquid-formulated recombinant BoNT/A, delivered via a prefilled device, represents a safer and more convenient option for users. The combination of a super-pure, highly effective product and its ease-of-use design offers BoNT/A users an optimized solution," said Dr. Wu Yang, Chief Scientific Officer of Claruvis, who has over 20 years of experience in botulinum toxin research and development. Claruvis Pharmaceutical, one of the few pioneering biotech companies in China, has developed the world's first recombinant BoNT/A product to reach clinical studies. The company recently completed its Phase III clinical trial for treatment of medium to severe glabellar lines and achieved all the study end points. The efficacy, safety and immunogenicity profiles demonstrated in the trial have set a remarkable milestone in the field of cosmetical use of BoNTs. On September 14th, the company has also successfully dosed the first patient in a phase II clinical trial for treatment of adult upper arm spasm in China, setting another new world record utilizing recombinant BoNT/A for the therapeutic indication. The company has started its first Biologics License Application (BLA) in China, backed by a comprehensive set of successful Phase I, II, and III clinical results. Dr. Yang added, "We believe the FDA's approval of YY003 for clinical evaluation is a significant milestone towards launching a high-quality product in the Botulinum toxin market." About MingMed MingMed Biotechnology Co., Ltd. is an innovative company dedicated to the in-house discovery and development of novel drugs that address global unmet medical needs. Our R&D team is led by global top-notch scientists and specialists. Leveraging our research and development capabilities and efficient operations, we have built an internally developed product portfolio with a diverse yet synergistic suite of four major therapeutic areas, namely recombinant botulinum toxin, ophthalmic drugs, immuno-oncology drugs and pet immune drugs. Our product pipelines include a number of first-in-class drug candidates, and the major products have moved forward to commercialization. About Claruvis Pharmaceutical Claruvis, a non-wholly owned subsidiary of MingMed Biotechnology, is strategically focus on the development, production and commercialization of botulinum toxin products utilizing recombinant protein technology. The R&D team is formed by top-notch global scientists and senior American Chinese scholars with in-depth knowledge and experience in botulinum toxin products. Marking a significant milestone, Claruvis has pioneered the development of the world's first recombinant type A BoNT product on a self-developed R&D platform. Excellent operational capability supported by a globally competitive R&D platform will continue to drive Claruvis' innovation and fast development in the rBoNT area to address the vast number of unmet aesthetic and therapeutic medical needs worldwide. Contact: [email protected] SOURCE MingMed Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Phase 2INDClinical Result

25 Jul 2024

·www.fiercepharma.com

With $111M upfront investment, Ipsen secures ex-US rights to Day One's pediatric cancer med

Cancer specialist Ipsen is signing on to help grow the reach of tovorafenib outside the U.S. Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine's global reach. Thursday, Day One and Ipsen unveiled an ex-U.S. licensing agreement for tovorafenib (approved as Ojemda in the U.S.) in pediatric low-grade glioma (pLGG) and "any future indications developed by Day One." In exchange for regulatory and commercial rights to tovorafenib outside the U.S., Ipsen is forking over $111 million upfront, including a $40 million equity investment in Day One. Based on potential success down the road, Day One could be in line for up to $350 million in milestones plus "tiered double-digit royalties." In a release, Ipsen said its "deep heritage and expertise in oncology" will allow the company to "accelerate the delivery of this innovation as teams focus on regulatory activities outside the U.S." As the company noted, patients with pLGG suffer from symptoms including vision and speech problems, neurological symptoms, fatigue, nausea and more. The disease can "significantly" impact a child's development and quality of life. The deal comes three months after Ojemda secured accelerated FDA approval as a treatment for pLGG in patients 6 months and older whose tumors have a BRAF fusion or rearrangement, or a BRAF V600 mutation. In their Thursday release, Ipsen and Day One described pLGG as the "most common childhood brain tumor." In the disease, Day One's drug is going up against Novartis' combination of Tafinlar and Mekinist, which in 2023 scored its own FDA nod to treat pLGG cases with BRAF V600 mutations, a more restricted use. Ojemda is California-based Day One's first commercial product and carries a peak sales estimate of $750 million from analysts at JPMorgan. As for Ipsen, the company separately on Thursday presented its first-half financial results. The drugmaker's first-half sales grew 8% year over year, reaching 1,659 billion euros ($1.8 billion). During the first half, Ipsen said its Exelixis-partnered cancer med Cabometyx and Dysport for spasticity and cervical dystonia drove its sales growth, along with Bylvay for patients with Alagille syndrome and Onvyide for certain cancers. While the company's profit margin declined slightly during the first six months of the year, Ipsen attributed the decrease to higher R&D spending. With the first half in the books, Ipsen said it expects a full-year sales increase of 7% compared with its prior guidance of 6%.

License out/inDrug ApprovalAccelerated ApprovalFinancial Statement

100 Deals associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

External Link

KEGG	Wiki	ATC	Drug Bank
D09764	AbobotulinumtoxinA (Ipsen Biopharm Ltd)	M03AX01	DB00083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Facial Dermatoses	CN	Ipsen Developments Ltd.	17 Jun 2020
Muscle Spasticity	US	Ipsen Biopharm Ltd.	14 Jun 2017
Limb spasticity	US	Ipsen Biopharm Ltd.	29 Jul 2016
Glabellar frown lines	US	Ipsen Biopharm Ltd.	29 Apr 2009
Torticollis	US	Ipsen Biopharm Ltd.	29 Apr 2009
Dystonia	FR	Ipsen SA	28 Jan 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Migraine Disorders	Phase 3	US	Ipsen SA	29 Sep 2023
Migraine Disorders	Phase 3	CA	Ipsen SA	29 Sep 2023
Migraine Disorders	Phase 3	CZ	Ipsen SA	29 Sep 2023
Migraine Disorders	Phase 3	FR	Ipsen SA	29 Sep 2023
Migraine Disorders	Phase 3	GE	Ipsen SA	29 Sep 2023
Migraine Disorders	Phase 3	DE	Ipsen SA	29 Sep 2023
Migraine Disorders	Phase 3	PL	Ipsen SA	29 Sep 2023
Migraine Disorders	Phase 3	ES	Ipsen SA	29 Sep 2023
Lower limb spasticity	Phase 3	US	Ipsen SA	01 May 2018
Multiple Sclerosis	Phase 3	US	Ipsen SA	01 Mar 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05277337 (STAR, CTgov)	Phase 4	Glabellar frown lines	150	Alluzience (Group 1 (Alluzience))	vdnwgqjyts(zxcwllpgnf) = lqfsqyhlae sbrfgwyopi (ljnekfhtjx, tqboszwhxw - jhfydpjmbc) View more	-	16 Feb 2024
				powder BoNT-A (BOTOX/Vistabel) (Group 2 (Powder BoNT-A: BOTOX/Vistabel))	vdnwgqjyts(zxcwllpgnf) = yhmtvbemol sbrfgwyopi (ljnekfhtjx, hdsxqecjau - vfhijryfpv) View more
MDS2022	Not Applicable	cervical dystonia	27	Dysport	rgsvnyxqkr(ktqqmcyipr) = fyvhdxwphb puojeqcwqh (vizahxbqvz ) View more	Positive	15 Sep 2022
				Botox/Xeomin	itqlvkeuna(slozsqjdnm) = ggyjqmltmz pzcfuymrjp (busxowdibm )
AAN2021	Not Applicable	cervical dystonia	-	AbobotulinumtoxinA 500U	kvxobdhuau(lrwlrmrdja) = nppgjbetzw hounubcecr (uddhoyaikz, 4.0)	-	13 Apr 2021
				Placebo	kvxobdhuau(lrwlrmrdja) = dumnbfingw hounubcecr (uddhoyaikz, 4.3)
NCT03736928 (CTgov)	Phase 2	Glabellar frown lines	401	placebo	srungfrvqe(trsmjygrhv) = xoitcyhqmr nacibpmlrf (ckixvxalsk, shejocomld - aovabwjcid) View more	-	11 Feb 2021
NCT04080882 (CTgov)	Phase 2	-	80	Placebo (Placebo)	znifykwdxv(yryfxhpcnc) = pnfoozhgcv dzisesuvxe (lvzjklibit, zcahrywgxz - fkiqhzlwra) View more	-	22 Jan 2021
				AbobotulinumtoxinA dose 1 (AbobotulinumtoxinA Dose 1)	znifykwdxv(yryfxhpcnc) = kiejrtdjxq dzisesuvxe (lvzjklibit, skbjghyrxi - ckckvueqdp) View more
NCT01732809 (CTgov)	Phase 4	Wrinkling of skin	19	AbobotulinumtoxinA (ABO) (Abobotulinumtoxin A)	oxjtbfcgtu(gkkobpiilg) = zoqbwdnoeb uhyvtvddih (hmsbopoepa, apdmhgegzp - wvmhzhpbuk) View more	-	17 Dec 2020
				OnabotulinumtoxinA (ONA) (Onabotulinumtoxin A)	oxjtbfcgtu(gkkobpiilg) = rmgcdjqupn uhyvtvddih (hmsbopoepa, dbketuedrw - qripedkduq) View more
AAN2020	Not Applicable	Meige Syndrome	43	OnabotulinumToxinA	tecfmpdqis(urjdqdsrfs) = ieuhddhmjd omzjpyvcfv (guazynnafd ) View more	-	14 Apr 2020
AAN2020	Not Applicable	-	-	OnabotulinumtoxinA	eljjagnckg(qlupywohuv) = mzdpusrywz zxhiwxketj (oongtuqxme )	-	14 Apr 2020
				AbobotulinumtoxinA	eljjagnckg(qlupywohuv) = kebyvwqxye zxhiwxketj (oongtuqxme )
MDS2019	Not Applicable	First line	-	AbobotulinumtoxinA	wuzdtdnzhq(pynwkerblk) = qdmrsoulhi iexhytrszn (bttqranhue )	Positive	22 Sep 2019
MDS2019	Phase 1	-	28	rBoNT-E	sybadhoddt(thacnpbbcp) = Most treatment-emergent adverse events were considered unrelated to treatment, and no unexpected treatment-related toxicities were identified with rBoNT-E or aboBoNT-A gwqxvgundt (mxuhbpgwgt )	Positive	22 Sep 2019
				aboBoNT-A

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis